Charged particle therapy for high-grade gliomas in adults: a systematic review

[1]  J. Fink,et al.  Radiation-induced brain injury in patients with meningioma treated with proton or photon therapy , 2021, Journal of Neuro-Oncology.

[2]  Diane D. Liu,et al.  A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma. , 2021, Neuro-oncology.

[3]  D. Georg,et al.  RBE variation in prostate carcinoma cells in active scanning proton beams: In-vitro measurements in comparison with phenomenological models. , 2020, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[4]  I. Toma-Dasu,et al.  Cancer risk after breast proton therapy considering physiological and radiobiological uncertainties. , 2020, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[5]  H. Friedman,et al.  Management of glioblastoma: State of the art and future directions. , 2020, CA: a cancer journal for clinicians.

[6]  R. Rengan,et al.  Scanning Beam Proton Therapy versus Photon IMRT for Stage III Lung Cancer: Comparison of Dosimetry, Toxicity, and Outcomes , 2020, Advances in radiation oncology.

[7]  Y. Mao,et al.  Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center , 2020, Cancer.

[8]  Joe Y. Chang,et al.  Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Wo,et al.  Proton beam radiotherapy for anal and rectal cancers. , 2020, Journal of gastrointestinal oncology.

[10]  G. Rubini,et al.  Proton versus Photon Radiotherapy for Pediatric Central Nervous System Malignancies: A Systematic Review and Meta-Analysis of Dosimetric Comparison Studies , 2019, Journal of oncology.

[11]  M. Massaccesi,et al.  Organs at risk's tolerance and dose limits for head and neck cancer re-irradiation: A literature review. , 2019, Oral oncology.

[12]  R. Slopsema,et al.  Impact of intrafraction prostate motion on clinical target coverage in proton therapy: A simulation study of dosimetric differences in two delivery techniques , 2019, Journal of applied clinical medical physics.

[13]  G. Chiang,et al.  Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis. , 2019, Radiologic clinics of North America.

[14]  Jonathan J. Evans,et al.  Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma. , 2019, The Cochrane database of systematic reviews.

[15]  W. Curry,et al.  Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  Takamitsu A Kato,et al.  Monoenergetic 290 MeV/n carbon-ion beam biological lethal dose distribution surrounding the Bragg peak , 2019, Scientific Reports.

[17]  Dennis R Schaart,et al.  Correlations between the shifts in prompt gamma emission profiles and the changes in daily target coverage during simulated pencil beam scanning proton therapy , 2019, Physics in medicine and biology.

[18]  Joe Y. Chang,et al.  Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues , 2019, Molecular Cancer.

[19]  A. Garden,et al.  Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer. , 2019, Oral oncology.

[20]  J. Unkelbach,et al.  Dosimetric comparison of protons vs photons in re-irradiation of intracranial meningioma. , 2018, The British journal of radiology.

[21]  M. Argyropoulou,et al.  Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas , 2018, Contrast media & molecular imaging.

[22]  L. Rosen,et al.  Safety and Efficacy of Proton Beam Therapy for High-Grade Glioma: Initial Report From the Proton Collaborative Group (PCG) , 2018, International Journal of Radiation Oncology*Biology*Physics.

[23]  J. Debus,et al.  Dosimetric Comparison of Proton Radiation Therapy, Volumetric Modulated Arc Therapy, and Three-Dimensional Conformal Radiotherapy Based on Intracranial Tumor Location , 2018, Cancers.

[24]  L. Uhlmann,et al.  Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma , 2018, Acta oncologica.

[25]  V. Budach,et al.  A novel voxel based homogeneity index: Rationale and clinical implications for whole-brain radiation therapy. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  Tracy Sa Underwood,et al.  Proton relative biological effectiveness (RBE): a multiscale problem. , 2018, The British journal of radiology.

[27]  J. Raizer.  Faculty Opinions recommendation of CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. , 2018 .

[28]  T. Akimoto,et al.  Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma , 2018, Radiation oncology.

[29]  P. Wesseling,et al.  WHO 2016 Classification of gliomas , 2018, Neuropathology and applied neurobiology.

[30]  I. Gibbs,et al.  Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma. , 2018, Neurosurgery.

[31]  Christopher U. Jones,et al.  NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients , 2018, Journal of Neuro-Oncology.

[32]  J. Debus,et al.  Sequential proton boost after standard chemoradiation for high-grade glioma. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  Panayiotis Mavroidis,et al.  Dosimetric and radiobiological comparison for quality assurance of IMRT and VMAT plans , 2017, Journal of applied clinical medical physics.

[34]  Markus Alber,et al.  Adaptation is mandatory for intensity modulated proton therapy of advanced lung cancer to ensure target coverage. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[35]  Ludvig Paul Muren,et al.  Functional image-guided dose escalation in gliomas using of state-of-the-art photon vs. proton therapy , 2017, Acta oncologica.

[36]  Radhe Mohan,et al.  Proton therapy - Present and future. , 2017, Advanced drug delivery reviews.

[37]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.

[38]  Ana Ureba,et al.  Dosimetric Comparison of Plans for Photon- or Proton-Beam Based Radiosurgery of Liver Metastases. , 2016, International journal of particle therapy.

[39]  G. Rath,et al.  Management of glioblastoma after recurrence: A changing paradigm. , 2016, Journal of the Egyptian National Cancer Institute.

[40]  H. Ishikawa,et al.  Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide , 2016, Journal of Neuro-Oncology.

[41]  K. Herfarth,et al.  Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma , 2016, Strahlentherapie und Onkologie.

[42]  Joe Y. Chang,et al.  A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis , 2016, Scientific Reports.

[43]  M. Chua,et al.  Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme , 2016, OncoTargets and therapy.

[44]  L. Morgan,et al.  The epidemiology of glioma in adults: a "state of the science" review. , 2015, Neuro-oncology.

[45]  S. Miyatake,et al.  Long-term survival after treatment of glioblastoma multiforme with hyperfractionated concomitant boost proton beam therapy. , 2015, Practical radiation oncology.

[46]  Harald Paganetti,et al.  Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer , 2014, Physics in medicine and biology.

[47]  M. Alonso-Basanta,et al.  Acute Toxicity Profile of Patients with Low-grade Gliomas and Meningiomas Receiving Proton Therapy , 2014, American journal of clinical oncology.

[48]  J. Barnholtz-Sloan,et al.  The epidemiology of glioma in adults: a "state of the science" review. , 2014, Neuro-oncology.

[49]  J. Debus,et al.  Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro , 2013, Radiation oncology.

[50]  N. Nonoguchi,et al.  Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid PET. , 2013, Japanese journal of clinical oncology.

[51]  H. Mehdorn,et al.  Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma , 2013, Journal of Clinical Neuroscience.

[52]  Ø. Fluge,et al.  Pseudoprogression in high‐grade glioma , 2013, Acta neurologica Scandinavica. Supplementum.

[53]  Lei Wang,et al.  Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma , 2013, Neurosurgical Review.

[54]  Jürgen Debus,et al.  First experiences in treatment of low-grade glioma grade I and II with proton therapy , 2012, Radiation oncology.

[55]  T. Kataria,et al.  Homogeneity Index: An objective tool for assessment of conformal radiation treatments , 2012, Journal of medical physics.

[56]  R. Howell,et al.  Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma , 2012, Radiation oncology.

[57]  K. Takakura,et al.  Experience with carbon ion radiotherapy for WHO Grade 2 diffuse astrocytomas. , 2012, International journal of radiation oncology, biology, physics.

[58]  S. Both,et al.  Dosimetric comparison of combined intensity-modulated radiotherapy (IMRT) and proton therapy versus IMRT alone for pelvic and para-aortic radiotherapy in gynecologic malignancies. , 2012, International journal of radiation oncology, biology, physics.

[59]  P. Rosenschöld,et al.  Photon and proton therapy planning comparison for malignant glioma based on CT, FDG-PET, DTI-MRI and fiber tracking , 2011, Acta oncologica.

[60]  W. Franklin,et al.  Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. , 2010, International journal of radiation oncology, biology, physics.

[61]  A. Unterberg,et al.  glioblastoma: The CLEOPATRA Trial , 2022 .

[62]  H. Igaki,et al.  Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. , 2010, International journal of radiation oncology, biology, physics.

[63]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[64]  J. Debus,et al.  Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines , 2008, International journal of radiation biology.

[65]  Zuofeng Li,et al.  Proton therapy coverage for prostate cancer treatment. , 2008, International journal of radiation oncology, biology, physics.

[66]  K. Takakura,et al.  Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[67]  A. Matsumura,et al.  Cell cycle checkpoint and apoptosis induction in glioblastoma cells and fibroblasts irradiated with carbon beam. , 2007, Journal of radiation research.

[68]  Myonggeun Yoon,et al.  A new homogeneity index based on statistical analysis of the dose–volume histogram , 2007, Journal of applied clinical medical physics.

[69]  C. Adair,et al.  Performance measurement in healthcare: part I--concepts and trends from a State of the Science Review. , 2006, Healthcare policy = Politiques de sante.

[70]  D. Misailidou,et al.  Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[72]  A. Karim,et al.  Endocrine functions in long-term survivors of low-grade supratentorial glioma treated with radiation therapy , 2005, Journal of Neuro-Oncology.

[73]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[74]  I. Paddick.  A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. , 2000, Journal of neurosurgery.

[75]  I. Paddick,et al.  A simple scoring ratio to index the conformity of radiosurgical treatment plans , 2001 .

[76]  P Okunieff,et al.  Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. , 1999, Journal of neurosurgery.

[77]  H. Tsujii,et al.  Clinical results of fractionated proton therapy. , 1993, International journal of radiation oncology, biology, physics.

[78]  H. Withers.  Biologic basis for altered fractionation schemes , 1985, Cancer.